JAMA Viewpoint argues FDA advisory committee peptide votes threaten the drug approval process

Summary. A Viewpoint published in the Journal of the American Medical Association (JAMA) on 26 October 2026 by three authors from the Center for Science in the Public Interest (CSPI), a consumer advocacy group, argues that following the July recommendations of FDA's Pharmacy Compounding Advisory Committee would expose the public to unproven peptides and undermine both the advisory committee system and FDA's drug approval process. It appears while FDA's notice "Interim Access Policy for Compounding Using Certain Peptides" (RIN 0910-ZD94) is still under White House review: reginfo.gov listed it as pending on 27 October, and its text, covered substances and conditions have not been published.

Research context (RUO). CSPI's release of 26 October summarizes four arguments. First, if FDA allowed compounding because of the size of an existing market, the same reasoning could be used for other unapproved products. Second, if peptides could reach patients through 503A compounding without the safety and effectiveness evidence required for approval, drug developers would have less reason to run clinical trials on peptide candidates. Third, CSPI writes that most of the committee's newly appointed permanent members had ties to peptide-related businesses and clinics and that every favorable vote came from them; the Viewpoint states that "when votes are, in effect, predetermined by selective appointments, the role of advisory committees as a mechanism to solicit independent expertise and adjudicate scientific uncertainty is fundamentally undermined." Fourth, it notes that a March 2026 FDA meeting considered whether peptides could be treated as dietary ingredients. FDAWeb reported the Viewpoint the same day. The JAMA article page itself could not be fetched (access check), so the arguments are attributed to CSPI's release and the JAMA Network media summary. The background is unchanged. FDA's own reviewers recommended against all seven peptides reviewed in July, concluding that none could be sufficiently characterized; the committee then voted to recommend six of the seven. That is a recommendation, and no FDA notice listing six peptides exists. Holland & Knight notes that adding any substance to the 503A bulks list requires FDA to publish a proposed rule, take public comment and issue a final rule, and that a near-term interim policy would most likely take the form of enforcement discretion, which approves no product. OIRA's meeting log lists six outside-party meetings on the notice, including two on 27 October (one requested by the Alliance for Pharmacy Compounding) and two on 28 October. In documentation terms, "characterization" means establishing what a material is and what else it contains: identity, purity and the impurity profile, the same results a lot-level certificate of analysis (COA) reports for one batch together with its lot number, test methods, laboratory and date.

Related: FDA Peptide Compounding Policy Tracker 2026, a sourced status page for the interim notice, the July advisory votes and the 503A bulks list.

This summary is for research-community awareness only and is not legal advice. For research use only. Not for human or veterinary use.